CLDN18.2 CAR-T

About Waypoint Bio

Waypoint Bio is an early-stage biotech developing AI-driven cell therapies for solid tumors, a major challenge in oncology. Its core innovation is a spatial pooled screening platform that tests thousands of cell therapy designs in a single in vivo experiment, using machine learning to rank and iteratively optimize candidates. The company has two disclosed CAR-T programs in discovery and lead optimization stages, targeting CLDN18.2 and an undisclosed antigen for gastric and lung/prostate cancers, respectively. Backed by a team with deep expertise in spatial biology, AI, and genomics, Waypoint aims to compress years of R&D into accelerated, data-rich development cycles.

Therapeutic Areas